BR112022021535A2 - Métodos para tratar agitação associada ao mal de alzheimer - Google Patents
Métodos para tratar agitação associada ao mal de alzheimerInfo
- Publication number
- BR112022021535A2 BR112022021535A2 BR112022021535A BR112022021535A BR112022021535A2 BR 112022021535 A2 BR112022021535 A2 BR 112022021535A2 BR 112022021535 A BR112022021535 A BR 112022021535A BR 112022021535 A BR112022021535 A BR 112022021535A BR 112022021535 A2 BR112022021535 A2 BR 112022021535A2
- Authority
- BR
- Brazil
- Prior art keywords
- alzheimer
- disease
- methods
- agitation associated
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016270P | 2020-04-27 | 2020-04-27 | |
| PCT/US2021/029246 WO2021222145A1 (en) | 2020-04-27 | 2021-04-26 | Methomethods of treating agitation associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021535A2 true BR112022021535A2 (pt) | 2023-01-24 |
Family
ID=75914613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021535A BR112022021535A2 (pt) | 2020-04-27 | 2021-04-26 | Métodos para tratar agitação associada ao mal de alzheimer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230270738A1 (enExample) |
| EP (1) | EP4142729A1 (enExample) |
| JP (1) | JP2023523373A (enExample) |
| KR (1) | KR20230016636A (enExample) |
| CN (1) | CN115734787A (enExample) |
| AU (1) | AU2021263354A1 (enExample) |
| BR (1) | BR112022021535A2 (enExample) |
| CA (1) | CA3176234A1 (enExample) |
| IL (1) | IL296977A (enExample) |
| MX (1) | MX2022013427A (enExample) |
| PH (1) | PH12022552764A1 (enExample) |
| TW (1) | TW202203922A (enExample) |
| WO (1) | WO2021222145A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2792662T3 (da) | 2007-05-01 | 2016-07-25 | Concert Pharmaceuticals Inc | Morphinanforbindelser |
| CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
| KR20240110812A (ko) * | 2021-10-27 | 2024-07-16 | 아바니르 파마슈티컬스, 인코포레이티드 | 알츠하이머병과 관련된 불안을 치료하는 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| US20160143901A1 (en) * | 2006-02-03 | 2016-05-26 | Avanir Pharmaceuticals, Inc. | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia |
| MX370608B (es) | 2007-05-01 | 2019-12-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
| TWI869633B (zh) * | 2014-09-14 | 2025-01-11 | 美商阿瓦尼爾製藥股份有限公司 | 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物 |
-
2021
- 2021-04-26 WO PCT/US2021/029246 patent/WO2021222145A1/en not_active Ceased
- 2021-04-26 EP EP21725652.8A patent/EP4142729A1/en not_active Withdrawn
- 2021-04-26 JP JP2023509465A patent/JP2023523373A/ja active Pending
- 2021-04-26 CA CA3176234A patent/CA3176234A1/en active Pending
- 2021-04-26 CN CN202180045685.XA patent/CN115734787A/zh active Pending
- 2021-04-26 BR BR112022021535A patent/BR112022021535A2/pt not_active IP Right Cessation
- 2021-04-26 PH PH1/2022/552764A patent/PH12022552764A1/en unknown
- 2021-04-26 MX MX2022013427A patent/MX2022013427A/es unknown
- 2021-04-26 AU AU2021263354A patent/AU2021263354A1/en not_active Abandoned
- 2021-04-26 KR KR1020227041229A patent/KR20230016636A/ko active Pending
- 2021-04-26 US US17/921,579 patent/US20230270738A1/en not_active Abandoned
- 2021-04-26 IL IL296977A patent/IL296977A/en unknown
- 2021-04-27 TW TW110115202A patent/TW202203922A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4142729A1 (en) | 2023-03-08 |
| IL296977A (en) | 2022-12-01 |
| WO2021222145A1 (en) | 2021-11-04 |
| US20230270738A1 (en) | 2023-08-31 |
| KR20230016636A (ko) | 2023-02-02 |
| TW202203922A (zh) | 2022-02-01 |
| WO2021222145A8 (en) | 2021-12-30 |
| PH12022552764A1 (en) | 2024-03-25 |
| MX2022013427A (es) | 2023-01-19 |
| AU2021263354A1 (en) | 2022-10-27 |
| JP2023523373A (ja) | 2023-06-02 |
| CN115734787A (zh) | 2023-03-03 |
| CA3176234A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Millstine et al. | Complementary and integrative medicine in the management of headache | |
| Çeçen et al. | The effect of hand and foot massage on fatigue in hemodialysis patients: A randomized controlled trial | |
| Masigati et al. | Postoperative pain management outcomes among adults treated at a tertiary hospital in Moshi, Tanzania. | |
| Azima et al. | The effect of isometric exercises on primary dysmenorrhea: A randomized controlled clinical trial | |
| MX2022013427A (es) | Metodos de tratamiento de la agitacion asociada a la enfermedad de alzheimer. | |
| Adams | Massage and Other CAM in Pregnancy. | |
| Hamilton et al. | Hospital treatment of patients with psychoneurotic disorders | |
| Nunes et al. | Effectiveness of physical and rehabilitation techniques in reducing pain in chronic trapezius myalgia: A systematic review and meta-analysis | |
| NAIK et al. | Effect of Physiotherapy in the Prevention and Relief of Secondary Lymphoedema in Subjects with Postoperative Breast Cancer-A Systematic Review of Randomised Controlled Trials. | |
| MX2024005154A (es) | Métodos de tratamiento de la agitación asociada a la enfermedad de alzheimer. | |
| Nurjannah | Fourteen days struggling to deal with COVID-19 using Su Jok Therapy: A case report | |
| Nithyanisha et al. | Efficacy of aerobic exercise and relaxation training in premenstrual symptoms in collegiates. | |
| Pratiwi | The Implementation of Valsava Manuever on Pain Reduction During IV Cannulation: A literature review | |
| Jain et al. | Transforming Menstrual Health: A Review of Yoga’s Effectiveness in Managing Primary Dysmenorrhea | |
| Khan et al. | Finger flexion to noxious stimulation in a brain-dead patient: a case report and review of literature | |
| Tavangar et al. | Evaluation of the effect of individual education-supported needs assessment for anxiety among elderly candidates of open-heart surgery | |
| Balinski et al. | The effectiveness of manual lymphatic drainage and low level laser'in the treatment of a client with lipedema': An N-of-1 trial | |
| Li et al. | Effect of Meridian-Based Acupuncture Combined with Tuina on Muscle Tension, Motor Development in Children with Spastic Cerebral Palsy. | |
| Poonai et al. | 116 hyoscine butylbromide (Buscopan) for abdominal pain in children: a randomized controlled trial | |
| Kadar et al. | Complex Regional Pain Syndrome in Distal Radius Fractures | |
| Mahmoudi et al. | Prevention of behavioral disorders through laughter therapy. | |
| Santos et al. | Therapeutic interventions associated with improvements in the quality of life of patients with fibromyalgia: a systematic review | |
| Ahn et al. | Complex regional pain syndrome type II after a brachial plexus and C6 nerve root injury | |
| Tsiami et al. | POS0262 VALUE OF SMALL FIBER NEUROPATHY IN FIBROMYALGIA PATIENTS IN A RHEUMATOLOGICAL SETTING | |
| Ko et al. | Cross-cultural Adaption And Reliability Of The Korean Version Of The Identification Of Functional Ankle Instability: 771 Board# 186 May 28, 200 PM-330 PM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2877 DE 24-02-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |